Category Archives: IP Rights

Five years after the Indian Supreme Court’s novartis verdict

Source: Intellectual Property Watch | May 21, 2018 On 1 April 2013, in a packed room inside India’s Supreme Court, a magnificent building in Indo-British architectural style, two judges delivered a verdict that impacted the national and global conversation about … Continue reading

Posted in Novartis Case, Sec 3 (d) | Leave a comment

Monsanto Can’t Have Patent on Bt Cotton in India, Court Says

Source: Bloomberg | April 11, 2018 Monsanto Co., the world’s largest seed company, can’t own a patent over genetically modified cotton seeds in India, a court ruled on Wednesday. The Delhi High Court verdict said that certain items such as … Continue reading

Posted in Court Cases, Patent, Patents | Leave a comment

U.S. wants patent form recall

Source: The Hindu | April 15, 2018 Submission on interpretation of a domestic patent law raises eyebrows The United States Patent and Trademark Office (USPTO) has demanded the elimination of ‘Form 27’— a statutory requirement unique to India’s patent law … Continue reading

Posted in Indian Patent Law, Indian Patent Office, IP Rights, IPR, Patent Enforcement, Patent infringement, US pressure on India | Leave a comment

Why do new medicines cost so much, and what can we do about it? The cost of new drugs is putting increasing pressure on people in both rich and poor countries. Sarah Boseley explains why it’s a burning issue

Source: The Guardian|April 09, 2018 Why does it matter what medicines cost? If you are lucky enough to live in a country with comprehensive state-funded healthcare, such as the UK, you probably have no idea how much medicines really cost. … Continue reading

Posted in Access to Medecines, Access to Medicins, Drug prices, IP Rights, Patent, Pricing, R&D | Leave a comment

Novartis must end ‘bullying tactics’ over life-saving medicines, campaigners says

Global protests ahead of Novartis AGM in Switzerland tomorrow Call for new CEO to clean up company following scandals in Colombia and Greece Thursday 1 March 2018 – Swiss multinational Novartis today faced international calls from an alliance of health … Continue reading

Posted in Compulsory Licensing, Generics, Novartis Case, Uncategorized | Leave a comment

German Federal Patent Court Determines License Fee for a Compulsory License under HIV Drug Patent

Source: All About IP On 21 November 2017, the German Federal Patent Court decided about a license fee for the HIV-Drug Isentress for which it has granted a compulsory license in 2016. Background of the Case In 2016, Shionogi & … Continue reading

Posted in IP Rights | Leave a comment

Perspectives on access to medicines and IP rights

Source: WIPO Magazine On average, people around the world are living significantly longer than their grandparents. In part, this is thanks to innovation in vaccines and to medicines reaching increasing numbers of patients. But as people live longer and new … Continue reading

Posted in Access to Medecines, IP Rights, IPR, Patent | Leave a comment